Transcenta Holding (HKSE:06628) Debt-to-Equity : 0.40 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Transcenta Holding Debt-to-Equity?

Transcenta Holding's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$417.45 Mil. Transcenta Holding's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$30.59 Mil. Transcenta Holding's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$1,124.00 Mil. Transcenta Holding's debt to equity for the quarter that ended in Dec. 2023 was 0.40.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Transcenta Holding's Debt-to-Equity or its related term are showing as below:

HKSE:06628' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.31 Med: 0.19 Max: 0.4
Current: 0.4

During the past 5 years, the highest Debt-to-Equity Ratio of Transcenta Holding was 0.40. The lowest was -0.31. And the median was 0.19.

HKSE:06628's Debt-to-Equity is ranked worse than
70.44% of 1069 companies
in the Biotechnology industry
Industry Median: 0.15 vs HKSE:06628: 0.40

Transcenta Holding Debt-to-Equity Historical Data

The historical data trend for Transcenta Holding's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transcenta Holding Debt-to-Equity Chart

Transcenta Holding Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.31

0.19

0.28

0.40

Transcenta Holding Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial				0.19	0.24	0.28	0.36	0.40

Competitive Comparison of Transcenta Holding's Debt-to-Equity

For the Biotechnology subindustry, Transcenta Holding's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Transcenta Holding's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transcenta Holding's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Transcenta Holding's Debt-to-Equity falls into.

Transcenta Holding Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Transcenta Holding's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(417.453	+	30.589)	/	1124.003
	=	0.40

Transcenta Holding's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(417.453	+	30.589)	/	1124.003
	=	0.40

Transcenta Holding (HKSE:06628) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Transcenta Holding Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Transcenta Holding's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Transcenta Holding (HKSE:06628) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transcenta Holding Ltd (HKSE:06628) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

B6-501, 218 Xinghu Street, Biobay, Suzhou, CHN, 215123

Website

https://www.transcenta.com

Transcenta Holding Ltd is a clinical stage biopharmaceutical company with fully integrated capacities in discovery, research, development and manufacturing. It is developing nine therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders. Geographically the company operates in China (the "PRC") and the USA.

Executives

Qian Xueming	2101 Beneficial owner
Shi Xiaohong	2501 Other
Lav Corporate Gp, Ltd.	2201 Interest of corporation controlled by you
Lav Gp Iii, L.p.	2201 Interest of corporation controlled by you
Lav Biosciences Fund Iii, L.p.	2101 Beneficial owner
Shi Yi	2201 Interest of corporation controlled by you
Lav Asset Management (hong Kong) Limited	2102 Investment manager
Fullerton Management Pte Ltd
Temasek Life Sciences Private Limited
Tls Beta Pte. Ltd.
Hsbc Trust Company (delaware), N.a.	2301 Trustee
Success Link International L.p.	2101 Beneficial owner
Temasek Holdings (private) Limited
Lav Vitality Limited	2101 Beneficial owner
Zhong Guo Guo You Qi Ye Jie Gou Tiao Zheng Ji Jin Gu Fen You Xian Gong Si	2501 Other

Transcenta Holding (HKSE:06628) Headlines

No Headlines